Vireo Growth (VREOF) Other Accumulated Expenses (2020 - 2025)

Vireo Growth (VREOF) reported Other Accumulated Expenses of $77128.0 for Q4 2025, down 83.93% sequentially from $479959.0 in Q3 2025.

Vireo Growth (VREOF) Other Accumulated Expenses (2020 - 2025) Analysis & Trends

Vireo Growth (VREOF) has 3 years of Other Accumulated Expenses data on file, last reported at $77128.0 in Q4 2025.

For the quarter ending Q4 2025, Other Accumulated Expenses changed N/A year-over-year to $77128.0; the trailing twelve-month figure through Dec 2025 stood at $77128.0 (changed N/A YoY), and the FY2025 full-year result was $77128.0, changed N/A from the prior year.
Other Accumulated Expenses declined to $77128.0 in Q4 2025, from $479959.0 in the prior quarter.
In the past five years, Other Accumulated Expenses ranged from a high of $720601.0 in Q3 2021 to a low of $77128.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Haleon	89.46 Bn	87.60 Bn	-
2	Teva Pharmaceutical Industries	35.93 Bn	32.19 Bn	1.97 Bn
3	Zoetis	32.54 Bn	30.60 Bn	1.62 Bn
4	Takeda Pharmaceutical	27.49 Bn	23.43 Bn	4.39 Bn
5	United Therapeutics	23.05 Bn	20.89 Bn	648.10 Mn
6	RedHill Biopharma	22.11 Bn	22.11 Bn	-
7	Viatris	20.24 Bn	18.43 Bn	1.16 Bn
8	Neurocrine Biosciences	17.77 Bn	16.45 Bn	800.70 Mn
9	Elanco Animal Health	12.60 Bn	12.17 Bn	785.00 Mn
10	Vireo Growth	10.51 Bn	10.36 Bn	59.30 Mn

Download Data